Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review

References

• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–915.
   PubMed Web of Science ®Google Scholar
• Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014;7:357–365.
   PubMedGoogle Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clinical Oncology: off Jl Am Soc Clin Oncol. 2012;30(17):2046–2054.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Horinouchi H, Yamamoto N, Fujiwara Y, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs. 2015;33(4):881–889.
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–465.
   PubMed Web of Science ®Google Scholar
• Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncology: off J Eur Soc Med Oncol. 2014;25(9):1750–1755.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clinical Oncology: off Jl Am Soc Clin Oncol. 2015;33(18):2013–2020.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol, Immunother: CII. 2012;61(7):1137–1147.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. Jama. 2014;312(17):1744–1753.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
   PubMed Web of Science ®Google Scholar
• Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5):997–1004.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncology: off J Eur Soc Med Oncol. 2013;24(1):75–83.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–886.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res: off J Am Assoc Cancer Res. 2015;21(4):712–720.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104–1111.
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (Hagerstown, Md: 1997). 2010;33(8):828–833.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 2015;11(17):2471–2484.
   Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf. 2015 Oct;14(10):1507–1518.
   Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 2016 Feb;12(3):413–425.
   Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7(11):1213–1227.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10:183–193.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol (Great Britain)). 2016;28:e127-e138.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy. 2016;8(5):665–674.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors; a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016;28(10):e127–38.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated 2011 Mar]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. New England J Med. 2016;374(26):2542–2552.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014;384(9948):1109–1117.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• De Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. New England J Med. 2016;375(3):296–297.
   PubMed Web of Science ®Google Scholar
• Maurice C, Schneider R, Kiehl TR, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3(12):1299–1302.
   PubMed Web of Science ®Google Scholar
• Altman AL, Golub JS, Pensak ML, et al. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngology–Head Neck Surg: off J Am Acad Otolaryngology-Head Neck Surg. 2015;153(5):894–895.
   PubMed Web of Science ®Google Scholar
• Carl D, Grullich C, Hering S, et al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes. 2015;8:316.
   PubMedGoogle Scholar
• Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother (Hagerstown, Md: 1997). 2015;38(2):77–79.
   PubMed Web of Science ®Google Scholar
• O’Kane GM, Lyons TG, Colleran GC, et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat. 2014;37(12):757–760.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clinical Oncology: off Jl Am Soc Clin Oncol. 2015;33(33):e122–4.
   PubMed Web of Science ®Google Scholar
• Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16(4):589–593.
   PubMed Web of Science ®Google Scholar
• Bot I, Blank CU, Boogerd W, et al. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–280.
   PubMedGoogle Scholar
• Manousakis G, Koch J, Sommerville RB, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48(3):440–444.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother (Hagerstown, Md: 1997). 2013;36(1):77–78.
   PubMed Web of Science ®Google Scholar
• Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clinical Oncology: off Jl Am Soc Clin Oncol. 2012;30(6):e76–8.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Huber BR, Upton MP, et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother (Hagerstown, Md: 1997). 2009;32(2):203–205.
   PubMed Web of Science ®Google Scholar
• Mandel JJ, Olar A, Aldape KD, et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1–2):229–231.
   PubMed Web of Science ®Google Scholar
• Stein MK, Summers BB, Wong CA, et al. Meningoencephalitis following ipilimumab administration in metastatic melanoma. Am J Med Sci. 2015;350(6):512–513.
   PubMed Web of Science ®Google Scholar
• Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598–601.
   PubMed Web of Science ®Google Scholar
• Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52(2):307–308.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697.
   PubMed Web of Science ®Google Scholar
• Juno permanently halts CAR T-cell study. Medscape. 2017 Mar 03.
   Google Scholar
• Zhu X, McDowell MM, Newman WC, et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr. 2017;19(2):249–253.
   PubMed Web of Science ®Google Scholar
• Qin L, Li X, Stroiney A, et al. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology. 2017;59(2):135–145.
   PubMed Web of Science ®Google Scholar
• Orloff M, Weight R, Valsecchi ME, et al. Immune check point inhibitors combination in melanoma: worth the toxicity? Rev Recent Clin Trials. 2016;11(2):81–86.
   PubMed Web of Science ®Google Scholar
• Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8.
   PubMed Web of Science ®Google Scholar